From a therapeutic perspective, a plasmid-based strategy (DTA-H19/BC-819) to target H19 is presently in a phase 2b clinical trial for bladder cancer and in phase 1/2a for ovarian and peritoneal cancer [87,88]. This evidence concerns the gene H19 and urinary bladder cancer.